Slingshot members are tracking this event:

Xenon (XENE) Phase 2 Topline Results for XEN801 in Moderate-to-Severe Acne

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details We have now surpassed 50% enrollment in our XEN801 Phase 2 clinical trial in patients with moderate to severe acne, and based on updated projections, we anticipate a read out of top-line results in the first quarter of 2017.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 24, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2, Xen801, Q4 2016, Topline Results